Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

CNS Medication Trials

Cincinnati, Ohio

CNS medication trials in Cincinnati, OH

50 CNS medication studies are recruiting participants at sites in Cincinnati as of November 17, 2026, according to ClinicalTrials.gov. CNS Medication Trials can help you understand your options and connect with a study team.

Call (888) 927-5768
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Cincinnati at a glance

  • 50 studies are recruiting at a site in Cincinnati.
  • By phase: Phase 1 (1), Phase 1/2 (1), Phase 2 (5), Phase 3 (34), Phase 4 (8), No phase (1). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (45), university, hospital or other (5).
  • By research area: Depression (13), Migraine (12), Parkinson's Disease (7), ADHD (5), Schizophrenia (5), Multiple Sclerosis (4), Bipolar Disorder (2), Epilepsy (2).
  • Most recent update to one of these records: November 17, 2026.

Depression studies recruiting in Cincinnati

Basic details from each study's public record (the 30 most recently updated of 50). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Intra-Cellular Therapies, Inc.
    Study site
    University of Cincinnati Medical Center
    Registry record
    NCT05850689 · updated
  2. Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients

    • Phase 3
    • Ages 10 to 17
    • All sexes
    Sponsor
    Intra-Cellular Therapies, Inc.
    Study site
    University of Cincinnati Medical Center
    Registry record
    NCT06372964 · updated
  3. Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

    • Phase 3
    • Ages 18 to 74
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Patient Priority Clinical Sites LLC
    Registry record
    NCT06559306 · updated
  4. A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder

    • Phase 3
    • Ages 12 to 17
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    University of Cincinnati
    Registry record
    NCT07227454 · updated
  5. A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 74
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Patient Priority Clinical Sites LLC
    Registry record
    NCT07573176 · updated
  6. Study of ALTO-300 in MDD

    • Phase 2
    • Ages 18 to 70
    • All sexes
    Sponsor
    Alto Neuroscience
    Registry record
    NCT05922878 · updated
  7. ALTO-207 in Adults With Treatment-resistant Depression (TRD)

    • Phase 2
    • Ages 18 to 75
    • All sexes
    Sponsor
    Alto Neuroscience
    Registry record
    NCT07553637 · updated

Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Cincinnati, OH on ClinicalTrials.gov.

Schizophrenia studies recruiting in Cincinnati

  1. A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)

    • Phase 3
    • Ages 13 to 17
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    University of Cincinnati Dept of Psychiatry and Behavioral Neuroscience
    Registry record
    NCT07288567 · updated
  2. A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents

    • Phase 3
    • Ages 5 to 17
    • All sexes
    Sponsor
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company
    Study site
    University of Cincinnati Cancer Institute
    Registry record
    NCT07424404 · updated
  3. Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

    • Phase 3
    • Ages 5 to 17
    • All sexes
    Sponsor
    Intra-Cellular Therapies, Inc.
    Study site
    University of Cincinnati Medical Center
    Registry record
    NCT06229210 · updated

Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in Cincinnati, OH on ClinicalTrials.gov.

Bipolar disorder studies recruiting in Cincinnati

  1. A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    University of Cincinnati Medical Center
    Registry record
    NCT06951711 · updated
  2. A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    University of Cincinnati Medical Center
    Registry record
    NCT06929273 · updated

Source: ClinicalTrials.gov. Data processed . See every bipolar disorder study recruiting in Cincinnati, OH on ClinicalTrials.gov.

ADHD studies recruiting in Cincinnati

  1. A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Otsuka Pharmaceutical Development & Commercialization, Inc.
    Study site
    Patient Priority Clinical Trials
    Registry record
    NCT07759154 · updated
  2. AWARE: Management of ADHD in Autism Spectrum Disorder

    • Phase 4
    • Ages 4 to 17
    • All sexes
    Sponsor
    Daniel Coury
    Study site
    Cincinnati Children's Hospital Medical Center
    Registry record
    NCT05916339 · updated

Source: ClinicalTrials.gov. Data processed . See every ADHD study recruiting in Cincinnati, OH on ClinicalTrials.gov.

Parkinson's disease studies recruiting in Cincinnati

  1. A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    University of Cincinnati Medical Center ( Site 0119)
    Registry record
    NCT06623422 · updated
  2. A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    University of Cincinnati Medical Center ( Site 5013)
    Registry record
    NCT06952504 · updated
  3. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Good Samaritan Hospital-TriHealth Cancer institute ( Site 0027)
    Registry record
    NCT06966700 · updated
  4. A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 5020)
    Registry record
    NCT07216703 · updated
  5. DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    AstraZeneca
    Registry record
    NCT06989112 · updated
  6. A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0103)
    Registry record
    NCT06345729 · updated

Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Cincinnati, OH on ClinicalTrials.gov.

Multiple sclerosis (MS) studies recruiting in Cincinnati

  1. A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

    • Phase 2
    • Ages 18 to 70
    • All sexes
    Sponsor
    Celgene
    Study site
    University of Cincinnati Medical Center
    Registry record
    NCT06782490 · updated
  2. Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

    • Phase 3
    • Ages 40 to 70
    • All sexes
    Sponsor
    Novartis Pharmaceuticals
    Study site
    Univ of Cincinnati Medical Center
    Registry record
    NCT06846281 · updated
  3. Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    TG Therapeutics, Inc.
    Study site
    TG Therapeutics Investigational Trial Site
    Registry record
    NCT05877963 · updated

Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in Cincinnati, OH on ClinicalTrials.gov.

Epilepsy studies recruiting in Cincinnati

  1. A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome

    • Phase 3
    • Ages 2 and older
    • All sexes
    Sponsor
    Epygenix
    Study site
    Cincinnati Children's Hospital Medical Center
    Registry record
    NCT04462770 · updated

Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in Cincinnati, OH on ClinicalTrials.gov.

Migraine studies recruiting in Cincinnati

  1. A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study site
    Headache Center of Hope
    Registry record
    NCT07816367 · updated
  2. Randomized Study in Children and Adolescents With Migraine: Acute Treatment

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    Pfizer
    Study site
    Cincinnati Children's Hospital Medical Center
    Registry record
    NCT04649242 · updated
  3. Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    Pfizer
    Study site
    Cincinnati Children's Hospital
    Registry record
    NCT04743141 · updated
  4. A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine

    • Phase 3
    • Ages 12 to 17
    • All sexes
    Sponsor
    H. Lundbeck A/S
    Study site
    Cincinnati Children's Hospital Medical Center-Burnet Campus
    Registry record
    NCT04965675 · updated
  5. Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    Pfizer
    Study site
    Cincinnati Children's Hospital Medical Center
    Registry record
    NCT05156398 · updated
  6. A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    H. Lundbeck A/S
    Study site
    Cincinnati Children's Hospital Medical Center-Burnet Campus
    Registry record
    NCT05164172 · updated

Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Cincinnati, OH on ClinicalTrials.gov.

Ask about studies near Cincinnati

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Ohio

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a medication, as each study is coded in the registry.

CNS Medication Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-5768

or send a short form

How should we reach you?

Call